Cargando…
Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations
AIMS: Fabry disease (FD) is often associated with heart failure (HF). However, data on HF prevalence, prognosis, and applicability of echocardiographic criteria for HF diagnosis in FD remain uncertain. METHODS AND RESULTS: We evaluated patients with genetically proven FD for symptoms and natriuretic...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773753/ https://www.ncbi.nlm.nih.gov/pubmed/36036737 http://dx.doi.org/10.1002/ehf2.14091 |
_version_ | 1784855257578209280 |
---|---|
author | Rob, Daniel Marek, Josef Dostalova, Gabriela Linhart, Ales |
author_facet | Rob, Daniel Marek, Josef Dostalova, Gabriela Linhart, Ales |
author_sort | Rob, Daniel |
collection | PubMed |
description | AIMS: Fabry disease (FD) is often associated with heart failure (HF). However, data on HF prevalence, prognosis, and applicability of echocardiographic criteria for HF diagnosis in FD remain uncertain. METHODS AND RESULTS: We evaluated patients with genetically proven FD for symptoms and natriuretic peptides indicating HF. We then analysed the diagnostic utility of the currently recommended European Society of Cardiology (ESC) echocardiographic criteria for HF diagnosis and their relationship to natriuretic peptides. Finally, we examined the association between HF and echocardiographic criteria with mortality and cardiovascular events during follow‐up. Of 116 patients with FD, 48 (41%) had symptomatic HF (mean age 58 ± 11 years, 62% male). HF with preserved ejection fraction (HF‐pEF) was diagnosed in 43 (91%) patients, representing the dominant phenotype. Left ventricular mass index (LVMi) had the highest diagnostic utility (sensitivity 71% and specificity 83%) for HF diagnosis in FD, followed by E/e′ > 9 (sensitivity 76% and specificity 78%) and global longitudinal strain (GLS) <16% (sensitivity 54% and specificity 88%). Log N‐terminal pro‐brain natriuretic peptide correlated significantly with LVMi (r = 0.60), E/e′ (r = 0.54), and GLS (r = 0.52) (all Ps < 0.001) but not with left ventricular ejection fraction (r = −0.034, P = 0.72). During follow‐up (mean 1208 ± 444 days), patients diagnosed with HF had a higher rate of all‐cause mortality and worsening HF (33% vs. 1.5%, P < 0.001). Abnormal LVMi, E/e′ > 9, and GLS < 16% were all associated with higher all‐cause mortality and worsening HF. CONCLUSIONS: This study found a high prevalence of symptomatic HF in FD patients. HF‐pEF was the dominant phenotype. LVMi, E/e′, and GLS yielded the highest diagnostic utility for HF diagnosis and were significantly correlated with natriuretic peptides levels. Echocardiographic criteria proposed by current ESC HF guidelines apply to Fabry patients and predict cardiovascular events. At follow‐up, Fabry patients with HF diagnosis had high event rates and significantly worse prognosis than patients without HF. |
format | Online Article Text |
id | pubmed-9773753 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97737532022-12-23 Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations Rob, Daniel Marek, Josef Dostalova, Gabriela Linhart, Ales ESC Heart Fail Original Articles AIMS: Fabry disease (FD) is often associated with heart failure (HF). However, data on HF prevalence, prognosis, and applicability of echocardiographic criteria for HF diagnosis in FD remain uncertain. METHODS AND RESULTS: We evaluated patients with genetically proven FD for symptoms and natriuretic peptides indicating HF. We then analysed the diagnostic utility of the currently recommended European Society of Cardiology (ESC) echocardiographic criteria for HF diagnosis and their relationship to natriuretic peptides. Finally, we examined the association between HF and echocardiographic criteria with mortality and cardiovascular events during follow‐up. Of 116 patients with FD, 48 (41%) had symptomatic HF (mean age 58 ± 11 years, 62% male). HF with preserved ejection fraction (HF‐pEF) was diagnosed in 43 (91%) patients, representing the dominant phenotype. Left ventricular mass index (LVMi) had the highest diagnostic utility (sensitivity 71% and specificity 83%) for HF diagnosis in FD, followed by E/e′ > 9 (sensitivity 76% and specificity 78%) and global longitudinal strain (GLS) <16% (sensitivity 54% and specificity 88%). Log N‐terminal pro‐brain natriuretic peptide correlated significantly with LVMi (r = 0.60), E/e′ (r = 0.54), and GLS (r = 0.52) (all Ps < 0.001) but not with left ventricular ejection fraction (r = −0.034, P = 0.72). During follow‐up (mean 1208 ± 444 days), patients diagnosed with HF had a higher rate of all‐cause mortality and worsening HF (33% vs. 1.5%, P < 0.001). Abnormal LVMi, E/e′ > 9, and GLS < 16% were all associated with higher all‐cause mortality and worsening HF. CONCLUSIONS: This study found a high prevalence of symptomatic HF in FD patients. HF‐pEF was the dominant phenotype. LVMi, E/e′, and GLS yielded the highest diagnostic utility for HF diagnosis and were significantly correlated with natriuretic peptides levels. Echocardiographic criteria proposed by current ESC HF guidelines apply to Fabry patients and predict cardiovascular events. At follow‐up, Fabry patients with HF diagnosis had high event rates and significantly worse prognosis than patients without HF. John Wiley and Sons Inc. 2022-08-29 /pmc/articles/PMC9773753/ /pubmed/36036737 http://dx.doi.org/10.1002/ehf2.14091 Text en © 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Rob, Daniel Marek, Josef Dostalova, Gabriela Linhart, Ales Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations |
title | Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations |
title_full | Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations |
title_fullStr | Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations |
title_full_unstemmed | Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations |
title_short | Heart failure in Fabry disease revisited: application of current heart failure guidelines and recommendations |
title_sort | heart failure in fabry disease revisited: application of current heart failure guidelines and recommendations |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9773753/ https://www.ncbi.nlm.nih.gov/pubmed/36036737 http://dx.doi.org/10.1002/ehf2.14091 |
work_keys_str_mv | AT robdaniel heartfailureinfabrydiseaserevisitedapplicationofcurrentheartfailureguidelinesandrecommendations AT marekjosef heartfailureinfabrydiseaserevisitedapplicationofcurrentheartfailureguidelinesandrecommendations AT dostalovagabriela heartfailureinfabrydiseaserevisitedapplicationofcurrentheartfailureguidelinesandrecommendations AT linhartales heartfailureinfabrydiseaserevisitedapplicationofcurrentheartfailureguidelinesandrecommendations |